Turning enzymes ON with small molecules.

Drug discovery and chemical genetic efforts typically focus on the identification and design of inhibitors or loss-of-function probes as a means to perturb enzyme function. These tools are effective in determining the physiological consequence of ablating the activity of a specific enzyme. Remarkably, nearly a dozen examples of non-natural small molecules that activate enzyme catalysis have been identified within the past decade. In aggregate, these studies delineate four unique activation mechanisms that the small molecules exploit. These complementary gain-of-function probes offer a way to address the sufficiency of an enzyme to drive a particular cellular phenotype, and they also provide new opportunities for drug discovery. This review covers the identification and characterization of these unique small-molecule activators.

[1]  L. Kifle,et al.  Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome. , 2006, Cell metabolism.

[2]  Jonathan V. Almaden,et al.  Glucose modulation of glucokinase activation by small molecules , 2008, Biochemistry.

[3]  Lawrence Shapiro,et al.  Crystal Structures of the Adenylate Sensor from Fission Yeast AMP-Activated Protein Kinase , 2007, Science.

[4]  B. Kemp,et al.  Functional Domains of the α1 Catalytic Subunit of the AMP-activated Protein Kinase* , 1998, The Journal of Biological Chemistry.

[5]  Peter J. Alaimo,et al.  Chemical genetic approaches for the elucidation of signaling pathways. , 2001, Current opinion in chemical biology.

[6]  K. Procházková,et al.  Structure-Function Analysis of Inositol Hexakisphosphate-induced Autoprocessing of the Vibrio cholerae Multifunctional Autoprocessing RTX Toxin* , 2008, Journal of Biological Chemistry.

[7]  David Carling,et al.  Structural basis for AMP binding to mammalian AMP-activated protein kinase , 2007, Nature.

[8]  A. Cornish-Bowden,et al.  Characteristics necessary for an interconvertible enzyme cascade to generate a highly sensitive response to an effector. , 1989, The Biochemical journal.

[9]  D. Mochly‐Rosen,et al.  Rationally designed peptide regulators of protein kinase C , 2009, Trends in Endocrinology & Metabolism.

[10]  Venkataraman Thanabal,et al.  SRT1720, SRT2183, SRT1460, and Resveratrol Are Not Direct Activators of SIRT1♦ , 2010, The Journal of Biological Chemistry.

[11]  D. Hardie Printed in U.S.A. Copyright © 2003 by The Endocrine Society doi: 10.1210/en.2003-0982 Minireview: The AMP-Activated Protein Kinase Cascade: The Key Sensor of Cellular Energy Status , 2022 .

[12]  S. Fields,et al.  Substrate-specific Activation of Sirtuins by Resveratrol* , 2005, Journal of Biological Chemistry.

[13]  Brian C. Smith,et al.  Mechanisms and molecular probes of sirtuins. , 2008, Chemistry & biology.

[14]  Amy V. Lynch,et al.  Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes , 2007, Nature.

[15]  Ricardo M Biondi,et al.  Phosphoinositide-dependent protein kinase 1, a sensor of protein conformation. , 2004, Trends in biochemical sciences.

[16]  J. Qin,et al.  Negative regulation of the deacetylase SIRT1 by DBC1 , 2008, Nature.

[17]  R. Heath,et al.  Defining the Mechanism of Activation of AMP-activated Protein Kinase by the Small Molecule A-769662, a Member of the Thienopyridone Family* , 2007, Journal of Biological Chemistry.

[18]  Susan S. Taylor,et al.  PKA-I Holoenzyme Structure Reveals a Mechanism for cAMP-Dependent Activation , 2007, Cell.

[19]  S. Hawley,et al.  5-aminoimidazole-4-carboxamide ribonucleoside. A specific method for activating AMP-activated protein kinase in intact cells? , 1995, European journal of biochemistry.

[20]  Susan S. Taylor,et al.  Signaling through cAMP and cAMP-dependent protein kinase: diverse strategies for drug design. , 2008, Biochimica et biophysica acta.

[21]  A. Chamberlin,et al.  Activation of protein phosphatase 1 by a small molecule designed to bind to the enzyme's regulatory site. , 2008, Chemistry & biology.

[22]  Tapas K. Kundu,et al.  Small Molecule Modulators of Histone Acetyltransferase p300* , 2003, Journal of Biological Chemistry.

[23]  M. Pal Recent advances in glucokinase activators for the treatment of type 2 diabetes. , 2009, Drug discovery today.

[24]  K. Shokat,et al.  Escape from HER family tyrosine kinase inhibitor therapy by the kinase inactive HER3 , 2007, Nature.

[25]  John Kuriyan,et al.  Protein-protein interactions in the allosteric regulation of protein kinases. , 2006, Current opinion in structural biology.

[26]  D. Mochly‐Rosen,et al.  Pharmacologic modulation of protein kinase C isozymes: the role of RACKs and subcellular localisation. , 1999, Pharmacological research.

[27]  B. Kemp,et al.  Thienopyridone drugs are selective activators of AMP-activated protein kinase beta1-containing complexes. , 2008, Chemistry & biology.

[28]  S. Tenzer,et al.  Autocatalytic cleavage of Clostridium difficile toxin B , 2007, Nature.

[29]  Junjie Chen,et al.  DBC1 is a negative regulator of SIRT1 , 2008, Nature.

[30]  Anthony C. Bishop,et al.  Brought to life: targeted activation of enzyme function with small molecules , 2009, Journal of chemical biology.

[31]  M. Disatnik,et al.  Activation of Aldehyde Dehydrogenase-2 Reduces Ischemic Damage to the Heart , 2008, Science.

[32]  J. Grippo,et al.  Allosteric Activators of Glucokinase: Potential Role in Diabetes Therapy , 2003, Science.

[33]  M. McVey,et al.  The SIR2/3/4 complex and SIR2 alone promote longevity in Saccharomyces cerevisiae by two different mechanisms. , 1999, Genes & development.

[34]  Susan S. Taylor,et al.  Assay principle for modulators of protein-protein interactions and its application to non-ATP-competitive ligands targeting protein kinase A. , 2006, Analytical chemistry.

[35]  K. Christopher Garcia,et al.  Mechanistic and structural insights into the proteolytic activation of Vibrio cholera MARTX toxin , 2009, Nature chemical biology.

[36]  P. Hergenrother,et al.  PAC-1 activates procaspase-3 in vitro through relief of zinc-mediated inhibition. , 2009, Journal of molecular biology.

[37]  D. Hardie,et al.  5-aminoimidazole-4-carboxamide ribonucleoside. A specific method for activating AMP-activated protein kinase in intact cells? , 1995, European journal of biochemistry.

[38]  R. Hartmann,et al.  3,5-Diphenylpent-2-enoic acids as allosteric activators of the protein kinase PDK1: structure-activity relationships and thermodynamic characterization of binding as paradigms for PIF-binding pocket-targeting compounds. , 2009, Journal of medicinal chemistry.

[39]  D. Sinclair,et al.  Nicotinamide and PNC1 govern lifespan extension by calorie restriction in Saccharomyces cerevisiae , 2003, Nature.

[40]  R. Silverman Implications for RNase L in prostate cancer biology. , 2003, Biochemistry.

[41]  C. Herrmann,et al.  Autocatalytic Processing of Clostridium difficile Toxin B , 2009, Journal of Biological Chemistry.

[42]  D. Schmoll,et al.  Biophysical Characterization of the Interaction between Hepatic Glucokinase and Its Regulatory Protein , 2008, Journal of Biological Chemistry.

[43]  P. Hergenrother,et al.  Reply to 'Small molecules not direct activators of caspases' , 2007, Nature Chemical Biology.

[44]  A. Cornish-Bowden,et al.  Evolution and regulatory role of the hexokinases. , 1998, Biochimica et biophysica acta.

[45]  Emad S. Alnemri,et al.  Crystal Structure of a Procaspase-7 Zymogen Mechanisms of Activation and Substrate Binding , 2001, Cell.

[46]  Stefan Zeuzem,et al.  Allosteric activation of the protein kinase PDK1 with low molecular weight compounds , 2006, The EMBO journal.

[47]  S. Sidhu,et al.  Two-state selection of conformation-specific antibodies , 2009, Proceedings of the National Academy of Sciences.

[48]  Benjamin F. Cravatt,et al.  Chemical strategies for the global analysis of protein function. , 2000 .

[49]  F. Matschinsky,et al.  Assessing the potential of glucokinase activators in diabetes therapy , 2009, Nature Reviews Drug Discovery.

[50]  Susan S. Taylor,et al.  Contribution of Non-catalytic Core Residues to Activity and Regulation in Protein Kinase A* , 2009, Journal of Biological Chemistry.

[51]  Brian K. Kennedy,et al.  Sirtuins in Aging and Age-Related Disease , 2006, Cell.

[52]  M. Gu,et al.  Small Molecule Antagonizes Autoinhibition and Activates AMP-activated Protein Kinase in Cells* , 2008, Journal of Biological Chemistry.

[53]  Chao Zhang,et al.  Inhibitor Hijacking of Akt Activation , 2009, Nature chemical biology.

[54]  J. Skehel,et al.  Interferon action—sequence specificity of the ppp(A2′p)nA-dependent ribonuclease , 1981, Nature.

[55]  C. Deng,et al.  Recent progress in the biology and physiology of sirtuins , 2009, Nature.

[56]  Zhi-Xin Wang,et al.  Structural insight into the autoinhibition mechanism of AMP-activated protein kinase , 2009, Nature.

[57]  K. Garcia,et al.  Small Molecule-Induced Allosteric Activation of the Vibrio cholerae RTX Cysteine Protease Domain , 2008, Science.

[58]  G. Salvesen,et al.  Structural basis for the activation of human procaspase-7 , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[59]  E. Holmes,et al.  The enzymatic synthesis of 5-amino-4-imidazolecarboxamide riboside triphosphate (ZTP). , 1984, Science.

[60]  Maria Deak,et al.  A phosphoserine/threonine‐binding pocket in AGC kinases and PDK1 mediates activation by hydrophobic motif phosphorylation , 2002, The EMBO journal.

[61]  A. Hattersley,et al.  Glucokinase mutations associated with non-insulin-dependent (type 2) diabetes mellitus have decreased enzymatic activity: implications for structure/function relationships. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[62]  D. Hardie,et al.  AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. , 2005, Cell metabolism.

[63]  D. Hardie,et al.  AMP-activated protein kinase as a drug target. , 2007, Annual review of pharmacology and toxicology.

[64]  M. Veiga-da-Cunha,et al.  Glucokinase regulatory protein is essential for the proper subcellular localisation of liver glucokinase , 1999, FEBS letters.

[65]  Maria Deak,et al.  Identification of a pocket in the PDK1 kinase domain that interacts with PIF and the C‐terminal residues of PKA , 2000, The EMBO journal.

[66]  P. Defossez,et al.  Requirement of NAD and SIR2 for life-span extension by calorie restriction in Saccharomyces cerevisiae. , 2000, Science.

[67]  Phuong Chung,et al.  Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan , 2003, Nature.

[68]  L. Kifle,et al.  Discovery and SAR development of thienopyridones: a class of small molecule AMPK activators. , 2007, Bioorganic & medicinal chemistry letters.

[69]  Klaus Aktories,et al.  Auto-catalytic Cleavage of Clostridium difficile Toxins A and B Depends on Cysteine Protease Activity* , 2007, Journal of Biological Chemistry.

[70]  S H Kaufmann,et al.  Mammalian caspases: structure, activation, substrates, and functions during apoptosis. , 1999, Annual review of biochemistry.

[71]  Teruyuki Nishimura,et al.  Structural basis for allosteric regulation of the monomeric allosteric enzyme human glucokinase. , 2004, Structure.

[72]  A. Cornish-Bowden,et al.  Response coefficients of interconvertible enzyme cascades towards effectors that act on one or both modifier enzymes. , 1992, European journal of biochemistry.

[73]  Y. Kitade,et al.  2‐5A induces a conformational change in the ankyrin‐repeat domain of RNase L , 2005, Proteins.

[74]  Timothy B. Stockwell,et al.  The Sequence of the Human Genome , 2001, Science.

[75]  J. Wells,et al.  A common allosteric site and mechanism in caspases , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[76]  G. Salvesen,et al.  Human Caspases: Activation, Specificity, and Regulation* , 2009, The Journal of Biological Chemistry.

[77]  Active regulator of SIRT1 cooperates with SIRT1 and facilitates suppression of p53 activity. , 2007, Molecular cell.

[78]  D E Koshland,et al.  Sensitivity amplification in biochemical systems , 1982, Quarterly Reviews of Biophysics.

[79]  Liang Tong,et al.  Crystal structure of the heterotrimer core of Saccharomyces cerevisiae AMPK homologue SNF1 , 2007, Nature.

[80]  Chao Zhang,et al.  Bypassing a Kinase Activity with an ATP-Competitive Drug , 2003, Science.

[81]  M. Magnuson,et al.  The network of glucokinase-expressing cells in glucose homeostasis and the potential of glucokinase activators for diabetes therapy. , 2006, Diabetes.

[82]  Christopher I. Bayly,et al.  Maintenance of caspase-3 proenzyme dormancy by an intrinsic “safety catch” regulatory tripeptide , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[83]  D. Mochly‐Rosen,et al.  Competitive inhibitors and allosteric activators of protein kinase C isoenzymes: a personal account and progress report on transferring academic discoveries to the clinic. , 2007, Biochemical Society transactions.

[84]  D. Haussler,et al.  A physical map of the human genome , 2001, Nature.

[85]  P. Hergenrother,et al.  Small-molecule activation of procaspase-3 to caspase-3 as a personalized anticancer strategy , 2006, Nature chemical biology.

[86]  G. Minasov,et al.  Structural and Molecular Mechanism for Autoprocessing of MARTX Toxin of Vibrio cholerae at Multiple Sites* , 2009, The Journal of Biological Chemistry.

[87]  J. Wells,et al.  Discovery of an allosteric site in the caspases. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[88]  Maria Deak,et al.  The PIF‐binding pocket in PDK1 is essential for activation of S6K and SGK, but not PKB , 2001, The EMBO journal.

[89]  B. Viollet,et al.  Mechanism of Action of A-769662, a Valuable Tool for Activation of AMP-activated Protein Kinase* , 2007, Journal of Biological Chemistry.

[90]  Jennifer L. Harris,et al.  Small molecules not direct activators of caspases , 2007, Nature Chemical Biology.

[91]  Y. Kitade,et al.  Structural basis for recognition of 2′,5′‐linked oligoadenylates by human ribonuclease L , 2004, The EMBO journal.

[92]  G. Salvesen,et al.  Caspases - controlling intracellular signals by protease zymogen activation. , 2000, Biochimica et biophysica acta.

[93]  J. Denu,et al.  The Sirtuin family: therapeutic targets to treat diseases of aging. , 2008, Current opinion in chemical biology.

[94]  Myriam Gorospe,et al.  Calorie Restriction Promotes Mammalian Cell Survival by Inducing the SIRT1 Deacetylase , 2004, Science.

[95]  James A. Wells,et al.  Small-Molecule Activators of a Proenzyme , 2009, Science.

[96]  Y. Kitade,et al.  Functional Characterization of 2′,5′-Linked Oligoadenylate Binding Determinant of Human RNase L* , 2005, Journal of Biological Chemistry.

[97]  M. Veiga-da-Cunha,et al.  Identification of Fructose 6-Phosphate- and Fructose 1-Phosphate-binding Residues in the Regulatory Protein of Glucokinase* , 2002, The Journal of Biological Chemistry.

[98]  David Loegering,et al.  Components of the Cell Death Machine and Drug Sensitivity of the National Cancer Institute Cell Line Panel , 2004, Clinical Cancer Research.

[99]  Junying Yuan,et al.  The Jekyll and Hyde functions of caspases. , 2009, Developmental cell.

[100]  P. Elliott,et al.  Sirtuins — novel therapeutic targets to treat age-associated diseases , 2008, Nature Reviews Drug Discovery.

[101]  Gaochao Zhou,et al.  AMPK: an emerging drug target for diabetes and the metabolic syndrome. , 2009, Cell metabolism.

[102]  R. Silverman,et al.  Small-molecule activators of RNase L with broad-spectrum antiviral activity , 2007, Proceedings of the National Academy of Sciences.

[103]  D. Hirschberg,et al.  Structure and allosteric effects of low-molecular-weight activators on the protein kinase PDK1. , 2009, Nature chemical biology.

[104]  J. Kuriyan,et al.  The Conformational Plasticity of Protein Kinases , 2002, Cell.

[105]  B. Stockwell Chemical genetics: ligand-based discovery of gene function , 2000, Nature Reviews Genetics.

[106]  J. Grimsby,et al.  Small molecule glucokinase activators as glucose lowering agents: a new paradigm for diabetes therapy. , 2006, Current medicinal chemistry.

[107]  Matt Kaeberlein,et al.  Sir2-Independent Life Span Extension by Calorie Restriction in Yeast , 2004, PLoS biology.

[108]  Helen Conroy,et al.  Caspase‐activation pathways in apoptosis and immunity , 2003, Immunological reviews.

[109]  David Komander,et al.  High resolution crystal structure of the human PDK1 catalytic domain defines the regulatory phosphopeptide docking site , 2002, The EMBO journal.